An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Maximum Tolerated Dose and Biomarker Response After Intravenous Administration of Weekly BAY80-6946 to Patients With Advanced Cancer

Bayer0 sites57 target enrollmentNovember 19, 2009

ConditionsNeoplasms

InterventionsCopanlisib (Aliqopa, BAY80-6946)

DrugsCopanlisib (Aliqopa, BAY80-6946)

Overview

Phase: Phase 1
Intervention: Copanlisib (Aliqopa, BAY80-6946)
Conditions: Neoplasms
Sponsor: Bayer
Enrollment: 57
Primary Endpoint: Characterize safety, tolerability + pharmacokinetics, to determine the maximum tolerated dose of BAY80-6946 administered 1x weekly for 3 weeks, every 4weeks, as a 1h-intravenous infusion. Evaluate biomarkers that may be predictive of tumor response.
Status: Completed
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

The purpose of this study is to determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.

Registry

clinicaltrials.gov

Start Date

November 19, 2009

End Date

February 23, 2016

Last Updated

8 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Bayer

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Age \>/= 18 years.
•Histological or cytological documentation of non-hematologic, malignant solid tumor, excluding primary brain or spinal tumors, or history of central nervous system metastases
•At least one measurable lesion or evaluable disease
•Life expectancy of at least 12 weeks
•ECOG Performance Status of 0, 1 or 2
•PT-INR/PTT \< 1.5 x upper limit of normal \[Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists\]. Low-dose aspirin is permitted (\</= 100 mg daily).
•Adequate bone marrow, liver and renal function
•Ability to understand and to sign an informed consent form; a signed informed consent must be obtained prior to any study specific procedures

Exclusion Criteria

•History of cardiac disease congestive heart failure (CHF) \> NYHA Class II; active coronary artery disease, myocardial infarction within 6 months prior to study entry; new onset angina within 3 months prior to study entry or unstable angina or cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or Digoxin are permitted).
•Current diagnosis of type I or II diabetes mellitus or fasting blood glucose level \>125 mg/dL at screening, or HbA1c 7%
•Active clinically serious infections \> Grade 2 (NCI-CTCAE Version 3.0)
•History of having received allogeneic organ transplant
•Uncontrolled seizure disorder. Use of cytochrome P450 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine or phenobarbital) is not allowed throughout the entire study.
•Uncontrolled hypertension defined as systolic blood pressure \> 150 mmHg or diastolic pressure \> 90 mmHg, despite optimal medical management

Arms & Interventions

Copanlisib

Intervention: Copanlisib (Aliqopa, BAY80-6946)

Outcomes

Primary Outcomes

Characterize safety, tolerability + pharmacokinetics, to determine the maximum tolerated dose of BAY80-6946 administered 1x weekly for 3 weeks, every 4weeks, as a 1h-intravenous infusion. Evaluate biomarkers that may be predictive of tumor response.

Time Frame: 2 years

Secondary Outcomes

Evaluate for early signs of efficacy in expansion cohorts(2 years)
Determine the effects of BAY80-6946 on blood glucose and insulin, and its safety in patients with type I or II diabetes.(2 years)